Nanoscope Therapeutics Press Releases
-
Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board
December 4, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress
December 1, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII
November 30, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit
November 9, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Awarded ‘Best of Show’ for Retina at Eyecelerator@AAO 2023
November 3, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2023
October 30, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Strengthens Research and Development Leadership with Appointment of Najam Sharif, PhD, DSc.
October 26, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 13th The Eye and the Chip World Research Congress
October 10, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at The Retina Society 56th Annual Scientific Meeting
October 9, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations in Upcoming Conferences
October 2, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 4th Annual Gene Therapy for Ophthalmic Disorders Summit
September 28, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Strengthens Clinical and Regulatory Expertise With Appointment of Samuel Barone, M.D., as Chief Medical Officer
September 21, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Unveils Clinical Trial Results for MCO-010 in Treating Stargardt Disease
August 9, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 2023 American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 21, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Participate in the Baird 2023 Biotech Discovery Series
June 12, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Participation in Upcoming Conferences
June 8, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the BIO International Convention
June 5, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the World Orphan Drug Congress
May 22, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting
April 27, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting
April 13, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
March 30, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic Advisor
March 20, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces World Health Organization Selection of “Sonpiretigene Isteparvovec” as International Nonproprietary Name for MCO-010
February 28, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics CEO Sulagna Bhattacharya Joins BIO Health Section Governing Board
February 13, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the BIO CEO & Investor Conference
February 2, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease
January 30, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the Optogenetics and Optical Manipulation Conference
January 23, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the Next Generation Ophthalmic Drug Delivery Summit
January 19, 2023 by Nanoscope Therapeutics
-
Nanoscope’s Top Executive Team to Participate in Advanced Therapies Week
January 11, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Appoints Massoud Motamed, PhD, as VP of Quality
January 5, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 by Wilson PJ
-
Nanoscope Therapeutics to Host Clinical Perspectives Panel to Discuss MCO-010 and the Treatment Landscape for Retinitis Pigmentosa and Stargardt Disease
November 10, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Expands Clinical and CMC Leadership Team with Gene Therapy Pharma Experience
November 7, 2022 by Nanoscope Therapeutics
-
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership
October 18, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Retinitis Pigmentosa
October 10, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 30, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
September 26, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease
September 13, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting
September 8, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at Baird’s 2022 Global Healthcare Conference
September 7, 2022 by Nanoscope Therapeutics
-
Nanoscope Announces Presentations at the 22nd Euretina Congress
August 29, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the Retina Forum 2022
August 26, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Move Corporate Headquarters to Dallas
August 16, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease
July 25, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit
July 14, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Gene Therapy to Restore Vision in Patients to be Featured at OIS Retina Innovation Summit and American Society of Retina Specialists Annual Meeting
July 12, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Top Executive Team to Participate and Present at World Orphan Drug Congress USA Meeting
July 11, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial Officer
July 5, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics CEO Sulagna Bhattacharya Named Winner of EY Entrepreneur Of The Year® 2022 Central Plains Award
June 27, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Provide Update on Optogenetic Approaches for Vision Restoration at BIO International
June 13, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Clinical Development of Optogenetics for Retinal Diseases to be Featured at Macula Society Meeting
June 6, 2022 by Nanoscope Therapeutics
-
Nanoscope Appoints Two Pharmaceutical Industry Veterans as Scientific and Clinical Advisors
May 25, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Clinical and Scientific Advances in Optogenetics to be Featured at ASGCT Annual Meeting, May 16-19, 2022 in Washington, DC
May 13, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Vision-Restoring Optogenetic Gene Therapy to be Featured in Multiple Presentations as Part of ARVO Annual Meeting in Denver May. 1-4, 2022
April 26, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Appoints Pharma Industry Veteran Aaron Osborne, MBBS, as Chief Medical Officer and Chief Development Officer
April 18, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces 3 New Appointments to its Scientific and Clinical Advisory Board
April 4, 2022 by Nanoscope Therapeutics
-
Nanoscope President to Present at Advancing Gene Therapy Summit March 30, 2022, in Boston, MA
March 28, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics CEO Sulagna Bhattacharya Elected to BIO Emerging Companies Section Governing Board
February 17, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to present at 2022 BIO CEO & Investor Conference
February 11, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision
February 7, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Five New Clinical and Scientific Advisory Board Appointments
February 1, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patients
January 25, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Vision Restoring Optogenetic Gene Therapy to be Featured in Four Presentations as part of SPIE Photonics West 2022
January 19, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Wins ‘2022 Biotech Innovation Award’
January 13, 2022 by Nanoscope Therapeutics
-
Nanoscope Awarded Key U.S. Patent Protecting Its Multi-Characteristic Opsin Gene Therapy Platform For Reversing Blindness
January 10, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Named Finalist for ‘Dallas Innovates and D CEO Magazine’ 2022 Innovation Award
December 22, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics’ Optogenetic Gene Therapy to be Featured in Presentation at Stanford University’s Innovate Retina Summit Dec. 11
December 8, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Wins ‘Top Retina Company’ Award at 2021 Eyecelerator Conference for Its Optogenetics Gene Therapy to Restore Vision in People Blinded by Retinal Diseases
December 3, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Co-Founder and President to Present at World Orphan Drug Congress Europe 2021, Nov. 17, in Barcelona, Spain
November 15, 2021 by Nanoscope Therapeutics
-
Nanoscope President to Present at Eyecelerator During American Academy of Ophthalmology 2021 Annual Meeting, Nov. 11, in New Orleans, LA
November 9, 2021 by Nanoscope Therapeutics
-
Positive Data from Nanoscope’s Phase 1/2a Trial of Gene Therapy to Restore Vision in Patients Blinded by Retinitis Pigmentosa to be Featured at 2021 American Society of Retina Specialists Meeting
October 8, 2021 by Nanoscope Therapeutics
-
Nanoscope President to Present at Company Showcase of the Ophthalmology Innovation Summit (OIS) Retina October 7, 2021, in San Antonio, TX
October 5, 2021 by Nanoscope Therapeutics
-
Positive Data of Optogenetic Gene Therapy for Patients Blinded by Retinitis Pigmentosa to be Presented at Retina Society’s Annual Conference
September 29, 2021 by Nanoscope Therapeutics
-
Nanoscope Awarded $1.5M Phase 2B SBIR Grant to Advance Ambient Light Activatable Opsin Gene Therapy to Restore Vision for AMD Patients
September 14, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentation of Positive Results from Optogenetic Gene Therapy for Retinal Degenerative Diseases at the EURETINA 2021 Virtual Conference
September 8, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa
July 19, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa
June 23, 2021 by Nanoscope Therapeutics
-
Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosa
June 3, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces New Clinical Advisory Board Appointments
April 19, 2021 by Nanoscope Therapeutics
-
Nanoscope’s Optical Gene Therapies to be Featured at Optogenetics and Optical Manipulation 2021 Conference
March 5, 2021 by Nanoscope Therapeutics
-
Nanoscope President to Deliver Talk on Gene Therapy for Retinal Diseases at Association for Ocular Pharmacology and Therapeutics Conference
March 3, 2021 by Nanoscope Therapeutics
-
Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of Health
February 2, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Receives Orphan Drug Designation for Gene Therapy of Blindness
January 25, 2021 by Nanoscope Therapeutics
-
Nanoscope Announces Presentation at the 2020 Annual Meeting of American Academy of Ophthalmology
November 13, 2020 by Nanoscope Therapeutics
-
Nanoscope received NIH support for its first-in-class delivery approach to restore vision
May 28, 2020 by Nanoscope Therapeutics
-
Nanoscope Receives NIH grants to recruit talent and advance optogenetic delivery platforms
January 25, 2020 by Nanoscope Therapeutics